Analogs of Luteinizing Hormone-releasing Hormone in Benign Prostatic Hyperplasia and Advanced Renal Cell Carcinoma
Author:
Comaru-Schally A. M.
Reference35 articles.
1. Aoyagi T., Takishima K., Hayakawa M. and Nakamura H. (1996). Gene expression of TGF-α, EGF and IL-6 in cultured renal tubular cells and renal cell carcinoma. Int J Urol, 3, 392–396.
2. Barry M. and Roehrborn C. (1997). Management of benign prostatic hyperplasia. Annu Rev Med, 48, 177–189.
3. Begun F.R, Story M.T., Hopp K.A., Shapiro E. and Lawson R.K. (1995). Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates. J Urol, 153, 839–843.
4. Cohen P., Peehl D.M., Baker B., Liu F., Hintz R.L. and Rosenfeld R.G. (1994). Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab, 79, 1410–1415.
5. Comaru-Schally A.M., Brannan W., Schally A.V., Colcolough M. and Monga M. (1998). Efficacy and safety of LHRH antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab, 83, 3826–3831.